Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Neuroblastoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Melanoma 1Medulloblastoma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 13Temozolomide 10Magnetic Resonance Spectroscopy 10dinutuximab 8X-Rays 8Specimen Handling 8Irinotecan 8Biopsy 8Phantoms, Imaging 7Topotecan 6Nuclear Medicine Department, Hospital 6fludarabine 5Vincristine 53-Iodobenzylguanidine 5fludarabine phosphate 4Granulocyte-Macrophage Colony-Stimulating Factor 4Etoposide 4tipifarnib 3sargramostim 3Radiotherapy 3Melphalan 3Isotretinoin 3Filgrastim 3Doxorubicin 3Carboplatin 3ulixertinib 2tazemetostat 2selpercatinib 2saponin QA-21V1 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroblastoma × Eflornithine × 90 days × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT02559778 2026-04-28

PEDS-PLAN

Milton S. Hershey Medical Center

Phase 2 Recruiting
500 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡